AnHeart Therapeutics is developing precision oncology therapeutics, including Taletrectinib for ROS1-positive non-small cell lung cancer and Safusidenib for IDH1-mutant gliomas and cholangiocarcinoma, both currently in Phase 2 clinical trials. The company targets specific genetic mutations in tumors to improve treatment efficacy and patient outcomes in cancer care.
Funding
$61M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OCFounders
Product
Problem
Many cancers are driven by specific genetic mutations, but traditional chemotherapy and radiation treatments lack the precision to target these mutations, leading to off-target effects and limited efficacy. This results in suboptimal patient outcomes and a need for therapies that selectively inhibit the growth of tumor cells harboring specific mutations.
Solution
AnHeart Therapeutics develops precision oncology therapeutics designed to target specific genetic mutations found in tumors. Their lead compounds, Taletrectinib and Safusidenib, are designed to selectively inhibit ROS1 and IDH1 mutations, respectively. By targeting these specific mutations, the company aims to improve treatment efficacy and patient outcomes while minimizing off-target effects. Both Taletrectinib and Safusidenib are currently in Phase 2 clinical trials for various cancers.
Target Audience
The primary target audience includes patients with ROS1-positive non-small cell lung cancer and IDH1-mutant gliomas and cholangiocarcinoma, as well as the oncologists and healthcare providers who treat them.
Features
- Taletrectinib: A ROS1 inhibitor in Phase 2 clinical trials for ROS1-positive non-small cell lung cancer.
- Safusidenib: A mIDH1 inhibitor in Phase 2 clinical trials for IDH1-mutant Grades 2 and 3 glioma, cholangiocarcinoma, and other tumors.
- Focus on developing therapies that target specific genetic mutations in tumors.